Boehringer Ingelheim Access to Healthcare Strategy last mile
We aspire to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world.
Search
Global Top Employer 2023
Global Top Employer 2023
AMR_Action_Fund
Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D
Partnering Approach Video 2023
Our Animal Health Business Development & Licensing team talks about Boehringer Ingelheim’s unique partnering approach and spirit of collaboration.
opening-solids-launch-fabrik
Boehringer Ingelheim today opened a tablet factory at Ingelheim in the presence of the State Premier of Rhineland-Palatinate, Malu Dreyer.
World Rabies Day 2020 sustainable dog vaccination
World Rabies Day 2020 sustainable dog vaccination
biolabs-heidelberg
Boehringer Ingelheim supports the launch of BioLabs first European Location in Heidelberg.
Partnering-with-google-in-quantum-computing
New cooperation with Google explores the potentials of quantum computing for pharma R&D.
Launch of BVDzero scholarship for veterinary students
Launch of BVDzero scholarship for veterinary students globally
EMA authorization for Reprocyc ParvoFLEX
Boehringer Ingelheim obtains EMA authorization for Reprocyc® ParvoFLEX, a new porcine parvovirus vaccine
New exchange platform with Harbin Research Institute
Boehringer Ingelheim and Harbin Veterinary Research Institute set up ‘industry-academia-research’ exchange platform
Groundbeaking of vaccine production center in France
Boehringer Ingelheim breaks ground on its strategic vaccine production center for veterinary public health
Open Innovation at Boehringer Ingelheim
Learn more about how we’re working across the innovation community to advance research and accelerate the development of new medicines
Fabio Paganini fostering inclusion & agility in AH
How employees are contributing to an inclusive culture at Boehringer Ingelheim.
cat feline diabetes medication treatment fda approval
Boehringer Ingelheim receives FDA approval for SENVELGO®
Partnering with Lifebit to detect global disease outbreaks
Boehringer Ingelheim partners with Lifebit to detect global infectious disease outbreaks
Dr. Hsing-Jung Chen-Engerer
Prioritizing development with Dr. Hsing-Jung Chen-Engerer
Our Partners Bioharmony
Chandra Ghose, Founder and CEO of Bioharmony Therapeutics, talks about the urgent need for developing new antimicrobials and the benefits of partnering with Boehringer Ingelheim.
Survey with Ipsos to gain insights human-animal bond
Boehringer Ingelheim partnered with the Ipsos Research Institute to carry out a survey to explore the human-animal bond.
Inauguration of new global center for veterinary vaccine R&D
Inauguration of a new global hi-tech centre for biological research and development in Lyon.
Joint venture to fight Antimicrobial Resistance
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
Central Data Science
Together with our business and IT colleagues, we develop data science-driven solutions, all the way from ideation to product.
Survodutide Phase III study weight loss
Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity
2024 half year results innovation progress
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Over 100 billion birds vaccinated with VAXXITEK
Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.